LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointData from EXPLORER-CN trial to be presented in an oral late-breaking science session at European Society of Cardiology Congress 2023Cash, cash equivalents and marketable securities of $267.3 million with runway into the first half of 2025
Source: yahoo.com